Quantitative values of simultaneous F-18 choline PET and diffusion-weighted imaging do not correlate in the assessment of intermediate prostate cancer—perhaps because the measurements characterize different tumor biology, according to a study published last month in PLOS ONE.

Abbott Laboratories based in Abbott Park, Ill., is receiving more than $19.5 million for the development of diagnostic biomarkers and assays for traumatic brain injury (TBI), the U.S. Department of Defense announced Aug. 13.

It may seem like an unlikely connection, but an aversion to kitty litter has led to a very interesting discovery about post-traumatic stress disorder (PTSD) that could one day lead to a diagnostic test and perhaps even a drug therapy,

GE Healthcare and NorthStar Medical RadioIsotopes have signed a letter of intent for the production and distribution of an American supply of medical isotopes, including the largest staple isotope, molybdenum-99 (Mo-99), NorthStar announced today.

A bioluminescence technique is being developed to monitor an adenovirus-mediated cancer gene therapy by following signs of apoptosis, or cell death, according to a study published online Aug. 13 in the journal Molecular Imaging.

A New York Times piece reviews recent research on the safety of potential Alzheimer’s therapies that focus on genetic factors of the disease. APOE is a hallmark risk factor and perhaps the most common in those who progress to Alzheimer’s, and often earlier than others.

A powerhouse of genomic information has led to a revamped tumor classification system that reclassifies as many as one out of every 10 cancer cases, according to a meta-analysis published Aug. 7 in the journal Cell.

Neuraceq (F-18 florbetaben) became available for commercial use on Aug. 1 and went into action for clinical PET imaging of beta-amyloid in the brain at WVU Healthcare in West Virginia, Piramal Imaging announced today.